The U.S. Food and Drug Administration (FDA) has approved the first all-oral, fixed-duration combination therapy for adults newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). “All-oral” means the medications are taken by mouth — no infusions or injections are needed. “Fixed-duration” means the treatment is given for a set amount of time, not indefinitely.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with your email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a Member? Log in

This approval adds a new first-line treatment option for people newly diagnosed with CLL or SLL. Because both medicines are taken by mouth, it may be more convenient than treatments that require infusions.

What Is the New Combo, and How Does It Work?

The newly approved combination includes two oral therapies that each target a different protein:

• Acalabrutinib (Calquence) — Blocks Bruton’s tyrosine kinase (BTK), helping slow or stop CLL cells from growing
• Venetoclax (Venclexta) — Blocks BCL-2, making it easier for cancer cells to die

Both medications were already approved to treat CLL. What’s new is the FDA approval of this specific all-oral, fixed-duration combination as an initial treatment for adults who are newly diagnosed.

What Did Clinical Trials Show?

The FDA based its decision on results from the phase 3 Amplify clinical trial. In this study, people who had not been treated before were randomly assigned to receive either the new all-oral combo or standard chemoimmunotherapy.

Key results from the study:

• The acalabrutinib-venetoclax combination reduced the risk of the cancer getting worse or death by 35 percent compared with standard chemoimmunotherapy.
• At a median follow-up of 42.6 months (about 3.5 years), people on the new combination were more likely to be alive without disease progression.
• Fewer deaths were reported in the group receiving the oral combination (6 percent) compared with those getting chemoimmunotherapy (14 percent).

Common and Rare Side Effects

As with all cancer treatments, side effects are possible. In the clinical trial, the most common side effects with the acalabrutinib-venetoclax combination were:

• Neutropenia (low white blood cell count)
• Headache
• Diarrhea
• Muscle and bone pain
• Infections, including COVID-19

Serious side effects included COVID-19 pneumonia, new cancers, and severe neutropenia. No new or unexpected safety issues were identified during the trial.

Both drugs also carry important warnings, including serious infections and bleeding. Venetoclax also has a warning for tumor lysis syndrome, a rare but serious condition that can happen when many cancer cells break down too fast.

Why This Matters for People With CLL

This approval gives people who are newly diagnosed with CLL or SLL a new first treatment option that’s both effective and more convenient. Because both medications are taken by mouth, treatment can happen at home, which may reduce time spent at infusion centers and offer more flexibility in daily life.

The treatment is also given for a set period — up to 14 cycles (just over a year) — rather than continuing indefinitely. For some people, a defined treatment timeline makes it easier to plan and offers a greater sense of control.

If you’re living with CLL or SLL and have questions about your treatment plan, talk with your healthcare provider. Your care team can review your current regimen and help you decide whether this newly approved option fits your personal treatment goals.

Join the Conversation

On MyLeukemiaTeam, people share their experiences with leukemia, get advice, and find support from others who understand.

Are you currently being treated for CLL? Let others know in the comments below.